{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:57:51Z","timestamp":1785301071531,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":386,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jchf.2023.01.004","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T14:01:55Z","timestamp":1677679315000},"page":"541-551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart\u00a0Failure With Reduced Ejection Fraction"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1517-5682","authenticated-orcid":false,"given":"Neal M.","family":"Dixit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil U.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9787-3649","authenticated-orcid":false,"given":"Boback","family":"Ziaeian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2023.01.004_bib1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2023.01.004_bib2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2010.165","article-title":"Epidemiology and risk profile of heart failure","volume":"8","author":"Bui","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jchf.2023.01.004_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.01.004_bib4","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jacc.2021.02.006","article-title":"Quadruple medical therapy for heart failure","volume":"77","author":"Greene Stephen","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.jchf.2023.01.004_bib5","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.01.004_bib6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure-optimizing therapy with the need for speed","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2023.01.004_bib7","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2023.01.004_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.14501","article-title":"Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction","volume":"4","author":"Isaza","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jchf.2023.01.004_bib9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/M16-0057","article-title":"Cost-effectiveness of sacubitril-valsartan in patients with heart failure with reduced ejection fraction","volume":"165","author":"Sandhu","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jchf.2023.01.004_bib10","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jamacardio.2021.1437","article-title":"Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction","volume":"6","author":"Parizo","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2023.01.004_bib11","first-page":"392","article-title":"Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction","volume":"4","author":"King","year":"2016","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.01.004_bib12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.01.004_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2023.01.004_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.01.004_bib15","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.01.004_bib16","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMc1509753","article-title":"Estimating the long-term treatment benefits of sacubitril-valsartan","volume":"373","author":"Claggett","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.01.004_bib17","first-page":"571","article-title":"Expenditure on heart failure in the United States: The Medical Expenditure Panel Survey 2009-2018","volume":"10","author":"Bhatnagar","year":"2022","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.01.004_bib18","unstructured":"Department of Veterans Affairs Federal Supply Schedule 2022. Accessed February 23, 2022. https:\/\/www.fss.va.gov"},{"key":"10.1016\/j.jchf.2023.01.004_bib19","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ejhf.1139","article-title":"Effect of sacubitril\/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart\u00a0Failure trial (PARADIGM-HF)","volume":"20","author":"Mogensen","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.01.004_bib20","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1161\/CIRCULATIONAHA.115.020729","article-title":"Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart\u00a0Failure Trial (PARADIGM-HF)","volume":"133","author":"Okumura","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.01.004_bib21","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.01.004_bib22","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of Tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.01.004_bib23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.01.004_bib24","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2023.01.004_bib25","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1017\/S0266462321001732","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"38","author":"Husereau","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.jchf.2023.01.004_bib26","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1016\/j.jacc.2022.04.031","article-title":"Medicare coverage and out-of-pocket costs of quadruple drug therapy for heart failure","volume":"79","author":"Faridi","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.01.004_bib27","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"63","author":"Anderson","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.01.004_bib29","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.01.004_bib30","article-title":"Cost-effectiveness of ivabradine for heart failure in the United States","volume":"5","author":"Kansal","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2023.01.004_bib31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/M14-1804","article-title":"Cost-effectiveness of adding cardiac resynchronization therapy to an implantable cardioverter-defibrillator among patients with mild heart failure","volume":"163","author":"Woo","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jchf.2023.01.004_bib32","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/clc.22696","article-title":"Cost-effectiveness of remote cardiac monitoring with the CardioMEMS heart failure system","volume":"40","author":"Schmier","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jchf.2023.01.004_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.007094","article-title":"Economic evaluation of catheter ablation of atrial fibrillation in patients with heart failure with reduced ejection fraction","volume":"13","author":"Chew","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jchf.2023.01.004_bib34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/M18-0992","article-title":"Catheter ablation of atrial fibrillation in patients with heart failure: a meta-analysis of randomized controlled trials","volume":"170","author":"Turagam","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jchf.2023.01.004_bib35","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/CIRCULATIONAHA.119.043275","article-title":"Cost-effectiveness of transcatheter mitral valve repair versus medical therapy in patients with heart failure and secondary mitral regurgitation: results from the COAPT trial","volume":"140","author":"Baron","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.01.004_bib36","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","article-title":"Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease","volume":"2","author":"Fonarow","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2023.01.004_bib37","first-page":"455","article-title":"Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes","volume":"27","author":"Guzauskas","year":"2021","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.jchf.2023.01.004_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100625","article-title":"Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England","volume":"29-30","author":"Cherla","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jchf.2023.01.004_bib39","first-page":"1","article-title":"Prescription drug accessibility and affordability in the United States and abroad","volume":"89","author":"Morgan","year":"2010","journal-title":"Issue Brief (Commonw Fund)"},{"key":"10.1016\/j.jchf.2023.01.004_bib40","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijcard.2021.01.061","article-title":"Real-world effectiveness and safety of sacubitril\/valsartan in heart failure: a systematic review","volume":"331","author":"Proudfoot","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2023.01.004_bib41","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jchf.2023.01.004_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF Trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2023.01.004_bib43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.121.054034","article-title":"Implantable cardioverter-defibrillator eligibility after initiation of sacubitril\/valsartan in chronic heart failure: insights from PROVE-HF","volume":"144","author":"Felker","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.01.004_bib44","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego Carlos","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.01.004_bib45","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.01.004_bib46","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003430","article-title":"Health-related quality of life outcomes in PARADIGM-HF","volume":"10","author":"Lewis","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2023.01.004_bib47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF Trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221317792300032X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221317792300032X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:02:43Z","timestamp":1761973363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221317792300032X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S221317792300032X"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2023.01.004","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart\u00a0Failure With Reduced Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2023.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}